Preventative and Public Health Research Initiatives - Targeted Health Systems and Community Organisation



Notice of Intent (NOI) registration OPEN

10am, 13 Jan 2020 (Monday)

Draft Grant Proposal due to RIC for strategic review. Early submission encouraged.

5pm, 22 Jan 2020 (Wednesday)

Draft application due to RIC for compliance and eligibility check (including other supporting documents)

5pm, 22 Jan 2020 (Wednesday)

Minimum Data due on RGMS

10am, 3 Feb 2020 (Monday)

Authority to Submit due to RIC

5pm, 3 Feb 2020 (Monday)

Final application submitted to RIC

5pm, 5 Feb 2020 (Wednesday)

Final application submitted to NHMRC


The Targeted Health System and Community Organisation Research Grant Opportunity which is part of the Preventative and Public Health Research Initiatives will focus on comparative effectiveness of health services and areas of health system practice with low or insubstantial evidence.

The objective of this grant opportunity is to support research that addresses five questions (see summary of questions below) developed by:
- Medical Services Advisory Committee (MSAC)
- Pharmaceutical Benefits Advisory Committee (PBAC)
- Prostheses List Advisory Committee (PLAC)
- Advisory Committee on Medical Devices (ACMD)
- Advisory Committee on Medicines (ACM) or
- The Medicare Benefits Review Taskforce (MBS Review Taskforce).

Summary of Questions: (Note: You must consult  Section 1.3 of the Grant Guidelines full description of specific objectives, research activities and outcomes.)

Question 1 Cancer treatment population

Summarised Objective to inform PBAC and MSAC decisions: to determine for a nominated cancer, the projected number of patients likely to require treatment at different stages over the next 5 years? Priority cancers include non-small cell lung cancer, breast cancer, bowel cancer, multiple myeloma, melanoma and pan-tumour biomarkers (eg. MSI-H, NTRK fusion).

Question 2 Tools to value health change in paediatric populations

Summarised Objectives to inform PBAC (and similar) decisions; How to value changes in child health for use in economic evaluation (specifically cos-utility analysis) and PBAC (and similar) decision making?

Are quality adjusted life years (QALYs) in pediatric populations comparable to those derived in adult populations, and if not, how should policy makes make decisions?

Question 3 Efficient use of high cost pharmaceuticals

Summarised Objective to inform PBAC decisions: For the specific medicine, are there more efficient ways to use the medicine for a indication without compromising effectiveness? Priority areas include biologicals for inflammatory disease and asthma, and PDL1 inhibitors and other biologics for cancer.

Question 4 Digital breast tomosynthesis

Summarised Objectives to inform MSAC decisions; Is digital breast tomosynthesis more clinically effective and cost effective compared to 2D mammography alone, OR ultrasound in the following three population groups:

  • Population 1: Patients with symptoms or signs of possible breast cancer
  • Population 2: Patients who had been previously diagnosed with breast cancer, with or without current symptoms of breast disease; and
  • Population 3: Patients with a risk of developing breast cancer due to their family history, with or without current symptoms.

Is digital breast tomosynthesis more effective in identifying breast cancer in women with dense breasts for each of the three population groups?

Question 5 Circumcision revision

Summarised Objective: how many primary circumcision surgeries result in the need for circumcision revision and how can the need for circumcision revision be reduced?


The Australian Government has announced a total of $260.4 million for the Preventive and Public Health Research Initiative. For this grant opportunity, up to $26.14 million of funding is available from 2019-20.

$7.96m $18.8m Nil Nil

There is no maximum grant amount but grants cannot exceed the amount of available funds for each year. The maximum grant period is four years.


- A person must not be named as a Chief Investigator (CI) on more than one application submitted to this grant opportunity. You are eligible to apply for more than one grant opportunity under the same PPHR initiatives.

- You are not eligible if your research proposal was submitted to the MRFF International Clinical Trial Collaboration (ICTC) Program and it is currently being assessed, or is included in the ICTC Merit List. Chief Investigators on an application submitted to the ICTC Program that is currently being assessed or is included in the ICTC Merit List are eligible to submit a different research proposal to this grant opportunity.

- The proposed research should not duplicate research previously or currently being undertaken. The NHMRC may compare the research proposed in grant applications with grants previously or currently funded by the MRFF, NHMRC or other agencies (e.g. Australian Research Council) and published research (see also section 4.7 – Other ineligible expenditure)

How to apply

  1. Notice of Intent: Please register your Notice of Intent if you are considering applying for the MRFF RCRDUN.  RIC-MRFF team will then contact each applicant with further information.
  2. Update RGMS Profile: Each CI must obtain access to RGMS and update profile information (see RGMS information)
  3. Review documentation: Review the grant guidelines and category descriptors available below and Grant Connect.
  4. Create and Complete the application:  Log in to RGMS select "MRFF - Research Grant" from Initiatives and then select the relevant scheme from Round and complete the application.
  5. Submit “Review Ready” application to RIC: Submit application to RIC within the RIC internal submission period for review.
  6. Complete application: After taking feedback from the RIC team into consideration, complete the application in RGMS. It is suggested advice is sought from colleagues, Faculty Mentors, etc. before finalising the application.
  7. Submit the UoM Authority to Submit Form:
  8. This form must be submitted to RIC electronically by the final internal closing date. This form should include:

    • Complete the compliance and eligibility section
    • Signature of all CIs and AIs
    • Signature of Head of Department for CIA

    Electronic signatures and email consent are permitted.

    This is an NHMRC requirement and the application cannot be submitted to NHMRC until received.

  9. Final Submission:
    • On the final internal closing date, the applicant must:
    • Submit finalised application by clicking ‘Submit to RAO’ in RGMS
    • Email RIC as well as a scanned, signed Authority to Submit form.
    • Should you require further information please contact Alvin Wong on 83449352 or via email
  10. RIC will submit the application: Once the application has been submitted to NHMRC, you will receive an email from RIC confirming submission.

Supporting documents

NHMRC Documents

Grant Guidelines

Assessment Criteria

Rating Scale for Overall Value and Risk

Minimum Data

RIC Documents

Summary and Tips

Grant Proposal Template (Including Assessment Criteria)

Authority to Submit Form

Wording for written consent


MRFF PPHR questions and primary email

Key Contacts

Alvin Wong and Catherine Nobes
T: Alvin - +61 3 8344 9352; Catherine - +61 3 8344 1471